Synektik Spólka Akcyjna Valuation

Is SNT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
zł322.92
Fair Value
27.2% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: SNT (PLN235) is trading below our estimate of fair value (PLN322.92)

Significantly Below Fair Value: SNT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNT?

Key metric: As SNT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SNT. This is calculated by dividing SNT's market cap by their current earnings.
What is SNT's PE Ratio?
PE Ratio24.1x
Earningszł83.10m
Market Capzł2.00b

Price to Earnings Ratio vs Peers

How does SNT's PE Ratio compare to its peers?

The above table shows the PE ratio for SNT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average78.9x
VOX Voxel
17.5x12.3%zł1.6b
NEU NEUCA
23.3x21.8%zł3.8b
ENE Centrum Medyczne ENEL-MED
84.2xn/azł588.2m
VHI Vitalhub
190.7x111.9%CA$618.2m
SNT Synektik Spólka Akcyjna
24.1x16.2%zł2.0b

Price-To-Earnings vs Peers: SNT is good value based on its Price-To-Earnings Ratio (24.1x) compared to the peer average (80.3x).


Price to Earnings Ratio vs Industry

How does SNT's PE Ratio compare vs other companies in the European Healthcare Services Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SNT 24.1xIndustry Avg. 34.7xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SNT is good value based on its Price-To-Earnings Ratio (24.1x) compared to the Global Healthcare Services industry average (34.7x).


Price to Earnings Ratio vs Fair Ratio

What is SNT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.1x
Fair PE Ratio21.7x

Price-To-Earnings vs Fair Ratio: SNT is expensive based on its Price-To-Earnings Ratio (24.1x) compared to the estimated Fair Price-To-Earnings Ratio (21.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł235.00
zł227.60
-3.1%
10.7%zł260.00zł200.00n/a4
Jan ’26zł198.60
zł209.08
+5.3%
15.8%zł260.00zł167.90n/a4
Dec ’25zł167.00
zł197.58
+18.3%
9.0%zł214.00zł167.90n/a4
Nov ’25zł178.60
zł197.58
+10.6%
9.0%zł214.00zł167.90n/a4
Oct ’25zł190.20
zł197.58
+3.9%
9.0%zł214.00zł167.90n/a4
Sep ’25zł148.80
zł158.67
+6.6%
9.2%zł170.00zł138.10n/a3
Aug ’25zł141.20
zł158.67
+12.4%
9.2%zł170.00zł138.10n/a3
Jul ’25zł147.20
zł158.67
+7.8%
9.2%zł170.00zł138.10n/a3
Jun ’25zł140.00
zł135.33
-3.3%
20.5%zł167.90zł100.00n/a3
May ’25zł129.20
zł119.05
-7.9%
16.0%zł138.10zł100.00n/a2
Apr ’25zł149.50
zł119.05
-20.4%
16.0%zł138.10zł100.00n/a2
Mar ’25zł131.50
zł119.05
-9.5%
16.0%zł138.10zł100.00n/a2
Feb ’25zł90.00
zł104.85
+16.5%
4.6%zł109.70zł100.00zł220.002
Jan ’25zł86.00
zł104.85
+21.9%
4.6%zł109.70zł100.00zł198.602
Dec ’24zł80.40
zł97.75
+21.6%
2.3%zł100.00zł95.50zł167.002
Nov ’24zł62.80
zł91.25
+45.3%
4.7%zł95.50zł87.00zł178.602
Oct ’24zł60.60
zł91.25
+50.6%
4.7%zł95.50zł87.00zł190.202
Sep ’24zł72.20
zł91.25
+26.4%
4.7%zł95.50zł87.00zł148.802
Analyst Price Target
Consensus Narrative from 4 Analysts
zł227.60
Fair Value
3.3% overvalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 01:42
End of Day Share Price 2025/02/06 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Synektik Spólka Akcyjna is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Adrian KowollikEast Value Research GmbH
Tomasz SokolowskiSantander Brokerage Poland